Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Gut bugs linked to liver damage in new study

NCT ID NCT07313007

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now This study
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study looks at how gut bacteria produce certain chemicals that might worsen fatty liver disease (MASLD). Researchers will collect stool, blood, and urine samples from 24 people with the condition and healthy volunteers. They aim to identify which bacteria are responsible for these harmful metabolites, which could lead to new treatments.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

What this could lead to
If successful, this could point toward new treatments for fatty liver disease by targeting gut bacteria.
What could go wrong
This is a small, early-stage observational study with only 24 participants, so results may not apply broadly and may not lead to treatments.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

About 24 people

The number the study aims to enrol. It can still change while the study runs.

Started

Jun 2026

Expected to finish

Jan 2027

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 to 80 years

Sex

Anyone

Healthy volunteers

Accepted

You do not need to have the condition being studied to take part.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * For patients and healthy volunteers: * Age between 18 and 80 years. * Non-diabetic participant (fasting blood glucose \< 1.26 g/L, or absence of insulin therapy or oral antidiabetic medication). * Body mass index (BMI) between 18 and 30 kg/m². * For women of childbearing potential, use of at least one recognized effective contraceptive method. * Very regular bowel movements every 24 to 48 hours. * Participant living within 100 km of the Lyon Sud Hospital Center (CHLS). * Participant willing to participate in the study and providing written informed consent. * Participant affiliated with the general French Social Security system or an equivalent scheme. * For patients: * Presence of MASLD according to the definition of the European Association for the Study of the Liver (EASL), defined by hepatic steatosis on imaging performed within the previous year (abdominal ultrasound, abdominal CT scan, magnetic resonance imaging, or controlled attenuation parameter (CAP) measured by FibroScan) and at least one cardiometabolic criterion among: dyslipidemia, arterial hypertension, overweight (BMI ≥ 25 kg/m²), impaired glucose tolerance, or type 2 diabetes. * No history of liver transplantation. * No excessive alcohol consumption (less than 20 g/day for women and less than 30 g/day for men). * Patient followed in the Endocrinology, Diabetes and Nutrition Department at Lyon Sud Hospital. Exclusion Criteria: * For patients and healthy volunteers: * Participant with active inflammatory, infectious, cardiovascular, or neoplastic disease. * Participant with a history of colectomy, small bowel resection, or cholecystectomy. * Participant who received antibiotics, prebiotics, or probiotics within the past 3 months. * Participant using laxatives (more than 2 doses per day over the past 3 months). * Participant with chronic constipation. * Pregnant, parturient, or breastfeeding women. * Participant deprived of liberty by judicial or administrative decision. * Participant receiving psychiatric care. * Participant institutionalized for reasons other than research. * Adult participant under legal protection (guardianship or trusteeship). * Participant who does not understand the French language and cannot provide informed consent. * Participant already enrolled in a study presenting a conflict of interest with the present study. * For healthy volunteers * Known liver disease * No long-term drug medication except oral contraception for women.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Masld (metabolic dysfunction-associated steatotic liver disease) are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    1 site. The list below names each one and where it is.

  2. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • Centre Hospitalier Lyon Sud Service Endocrinologie, Diabète et nutrition

    RECRUITING

    Pierre-Bénite, 69495, France

More trials for these conditions

Other studies related to the condition(s) this trial covers.